9 assets in Mitochondrial Disease

Therapeutic assets addressing Mitochondrial Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Sonlicromanol Mitochondrial Disease	Khondrion BV	P3	BB (70)
Trimetazidine Mitochondrial Disease	Steen Hvitfeldt Poulsen	P4	BB (69)
Mitoquinol Mesilate Mitochondrial Disease	Mclean Hospital	P2/3	B (57)
1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione Mitochondrial Disease	Kenneth Myers, MD	P2	CCC (53)
Doxecitine Mitochondrial Disease	Kenneth Myers, MD	P2	CCC (53)
Mnv-201 Mitochondrial Disease	Minovia Therapeutics Ltd.	P2	CCC (53)
Acetylcysteine Mitochondrial Disease	Michio Hirano, MD	P1	CC (43)
Omt-28 Mitochondrial Disease	Omeicos Therapeutics GmbH	P2	NR ()
Vatiquinone Mitochondrial Disease	PTC Therapeutics	P3	NR ()